GE inks deal with Draximage for nuclear cardiology expansion

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

GE Healthcare has entered into an agreement with Draximage, a division of Draxis Health of Montreal, to become the exclusive distributor of Draximage’s Sestamibi upon its approval by the FDA and the expiration of the primary innovator patent.

The FDA is currently reviewing an abbreviated New Drug Application for Draximage’s Sestamibi, submitted in February 2007.
John Chiminski, president and CEO of GE's medical diagnostics division, said that the agreement will expand its nuclear cardiology portfolio of radiopharmacy operation products.

Technetium-labeled radiopharmaceuticals, which include Myoview (a kit for the Preparation of Technetium Tc99m Tetrofosmin for injection), are used in approximately 90 percent of nuclear medicine studies performed to detect coronary artery disease, GE said.